ECSP088619A - Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva - Google Patents

Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva

Info

Publication number
ECSP088619A
ECSP088619A EC2008008619A ECSP088619A ECSP088619A EC SP088619 A ECSP088619 A EC SP088619A EC 2008008619 A EC2008008619 A EC 2008008619A EC SP088619 A ECSP088619 A EC SP088619A EC SP088619 A ECSP088619 A EC SP088619A
Authority
EC
Ecuador
Prior art keywords
treatment
combination
antagonist
inhibitor
acetilcolinesterase
Prior art date
Application number
EC2008008619A
Other languages
English (en)
Inventor
Lee Erwin Schechter
Thomas Anthony Comery
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088619A publication Critical patent/ECSP088619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención suministra un método para el tratamiento de un trastorno cognitivo tal como la enfermedad de Alzheimer en un paciente que lo necesita que comprende suministrar a dicho paciente una cantidad terapéuticamente efectiva de una combinación de un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6.
EC2008008619A 2006-01-13 2008-07-11 Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva ECSP088619A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75884106P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
ECSP088619A true ECSP088619A (es) 2008-08-29

Family

ID=38109582

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008619A ECSP088619A (es) 2006-01-13 2008-07-11 Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva

Country Status (20)

Country Link
US (1) US20070167431A1 (es)
EP (1) EP1971334A2 (es)
JP (1) JP2009523728A (es)
KR (1) KR20080096657A (es)
CN (1) CN101370499A (es)
AR (1) AR060019A1 (es)
AU (1) AU2007208516A1 (es)
BR (1) BRPI0706515A2 (es)
CA (1) CA2635920A1 (es)
CR (1) CR10139A (es)
EC (1) ECSP088619A (es)
GT (1) GT200800138A (es)
IL (1) IL192694A0 (es)
MX (1) MX2008009021A (es)
NO (1) NO20082894L (es)
PE (1) PE20071143A1 (es)
RU (1) RU2008126245A (es)
TW (1) TW200733976A (es)
WO (1) WO2007087151A2 (es)
ZA (1) ZA200806070B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
EP2254564A1 (en) * 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RU2467749C1 (ru) * 2011-04-21 2012-11-27 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции уровня сахара крови и лечения пациентов с сахарным диабетом второго типа с когнитивными нарушениями
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN107108556B (zh) * 2014-11-03 2020-09-29 艾欧米制药有限公司 药用化合物
WO2016179569A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
WO2017147601A1 (en) * 2016-02-25 2017-08-31 Axovant Sciences Gmbh Methods of improving balance, gait or both in patients with neurological disease
KR102473545B1 (ko) * 2016-04-26 2022-12-01 하. 룬드벡 아크티에셀스카브 파킨슨병 환자에서 낙상을 감소시키기 위한 아세틸콜린에스테라아제 억제제 및 아이달로피르딘의 용도
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
KR102015484B1 (ko) 2016-05-18 2019-08-28 수벤 라이프 사이언시스 리미티드 순수한 5-ht6 수용체 길항제와 아세틸콜린에스테라제 저해제의 조합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343756A2 (en) * 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2003279492A1 (en) * 2002-12-11 2004-06-30 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
CN100422171C (zh) * 2003-02-14 2008-10-01 惠氏公司 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
ZA200806070B (en) 2009-04-29
US20070167431A1 (en) 2007-07-19
GT200800138A (es) 2008-10-06
TW200733976A (en) 2007-09-16
MX2008009021A (es) 2008-09-24
CN101370499A (zh) 2009-02-18
IL192694A0 (en) 2009-02-11
JP2009523728A (ja) 2009-06-25
AU2007208516A8 (en) 2008-08-07
EP1971334A2 (en) 2008-09-24
NO20082894L (no) 2008-09-30
PE20071143A1 (es) 2008-01-20
CA2635920A1 (en) 2007-08-02
AR060019A1 (es) 2008-05-21
KR20080096657A (ko) 2008-10-31
CR10139A (es) 2008-09-30
AU2007208516A1 (en) 2007-08-02
RU2008126245A (ru) 2010-02-20
WO2007087151A3 (en) 2007-11-15
BRPI0706515A2 (pt) 2011-03-29
WO2007087151A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
CR10139A (es) "combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfusión congnitiva"
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
MX2009004106A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
BRPI1006115A2 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
PL2878297T3 (pl) Leki do leczenia lub zapobiegania chorobom zwłóknieniowym
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
GT200500098A (es) Nuevos compuestos
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
ECSP088811A (es) Compuestos orgánicos y sus usos
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CR10165A (es) "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión"
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
UY30986A1 (es) Derivados fluorinados de deferiprona
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
UY29995A1 (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.